The Drug Controller General of India (DGCI) on Saturday approved India’s first Clustered Regularly Interspaced Short Palindromic (CRISPR) Covid-19 test for market launch. This is developed by Tata and powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA (an acronym for FNCAS9 Editor-Limited Uniform Detection Assay).

This is the world’s first demonstrative test to convey an extraordinarily adjusted Cas9 protein to effectively distinguish the infection causing Covid-19.

“The approval for the Tata CRISPR test for COVID-19 will give a boost to the country’s efforts in fighting the global pandemic. The commercialization of the Tata CRISPR test reflects the tremendous R&D talent in the country, which can collaborate to transform India’s contributions to the global healthcare and scientific research world,” Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd, said.

With the tests getting cheaper, quicker, and way easier to use, it will help reduce the workload, stress and burden of the frontline heroes to some extent.

Checkout more such content at: https://gogomagazine.in/category/social/